As per the agreement, Pfizer will hold co-exclusive rights to CP-870,893 in the oncology vaccine field while VLST considers advancing the oncology compound into efficacy studies.
VLST president and chief executive officer Martin Simonetti said, "With the transfer of the IND from Pfizer, we will accelerate the development of our clinical strategy and expand our focus in immunotherapy to include oncology."
VLST completed a tranche of $5m Series B financing which will support the company’s Phase 2 clinical efforts.
Pfizer Oncology president and general manager Garry Nicholson said, "VLST’s expertise in immunotherapy makes the company a strong partner to continue the development of this compound and potentially deliver a new therapy to patients with cancer."